Mucosis B.V., a Groningen, The Netherlands-based clinical stage biotechnology company, secured €5.7m in funding.
The Wellcome Trust provided the funding.€3.7m translational fund award while current backers made an additional €2m equity investment.
The company, which had earlier secured €5m from the Netherlands Enterprise Agency (RVO), intends to use the funds to progress its proprietary intranasal Respiratory Syncytial Virus (RSV) vaccine, SynGEM®, into phase I and IIa human clinical trials.
Led by Tom Johnston, CEO, Mucosis uses a proprietary technology platform to develop needle-free human vaccines for infectious diseases. Its investigational vaccines can be delivered via the nose or mouth to elicit a more natural immune response. The company is developing multiple programs for its clinical-stage proprietary Mimopath® platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body. Its lead product SynGEM®, a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection, will enter human proof-of-concept studies in 2016. The company has also developed PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM®, a vaccine against influenza.